FDA approves AstraZeneca's Epanova, label update for Teva's Synribo; Researchers head to Twitter to identify drug problems;

> The FDA has green-lighted AstraZeneca's ($AZN) Epanova as a treatment for severe hypertriglyceridaemia in adults. Release

> The FDA has approved a label change for Teva's ($TEVA) Synribo injection that allows for home administration. Release

> A 6-week marketing suspension on Ariad's ($ARIA) chronic myeloid leukemia drug Iclusig has not negatively impacted how physicians view the drug, a survey found. More

> The U.S. diabetes market will reach $25 billion by 2020, with Sanofi ($SNY), Novo Nordisk ($NVO) and Eli Lilly ($LLY) leading the way, a new report says. Release

> An FDA panel will meet in October to review the risks of psychiatric and behavioral side effects associated with Pfizer's ($PFE) antismoking med Chantix. More

And Finally... Researchers have found that tapping into Twitter to read patient posts describing medication side effects could help them identify problems with drugs sooner. Story

Suggested Articles

Cardiac risks associated with roxadustat are comparable to placebo in nondialysis patients and to Amgen's standard, Epogen, in those on dialysis.

Pfizer and Merck KGaA's immuno-oncology agent Bavencio failed another gastric cancer study, this time as a maintenance treatment after chemotherapy.

A jury ordered Biogen to pay nearly $6 million to a former sales manager who reported a colleague's misconduct and got fired a few months later.